- About us
- Clinical trials
- News & Publications
SOTIO is developing SOT107 (formerly SO-N107) as an ADC against an undisclosed target.
SOT107 has demonstrated potent anti-tumor efficacy in vitro and in vivo and, due to NBE’s proprietary site-specific sortase mediated antibody coupling (SMAC) conjugation platform, has superior manufacturing properties including stability and aggregation propensity.